Continuous Intra-Intestinal Drug Composition for Stable Dopamine Levels

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for neurodegenerative disorders like Parkinson's disease face challenges due to fluctuations in levodopa plasma concentrations, leading to symptoms such as motor fluctuations and dyskinesias, as traditional therapies fail to maintain stable dopamine levels in the brain.

Innovation Solution

A method involving a pharmaceutical composition comprising a dopamine replacement agent, a dopamine decarboxylase inhibitor (DDI), and a catechol-O-methyltransferase (COMT) inhibitor, administered with a first high dose (20-35% of the total daily dose) followed by a continuous second dose to maintain stable plasma concentrations.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional levodopa therapy is used to treat Parkinson's disease, then dopamine replacement is achieved, but plasma concentration fluctuations occur leading to motor fluctuations and dyskinesias

Engineering Contradiction:

Improvestability of dopamine levelsVSAvoidmotor fluctuations and dyskinesias

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The total daily levodopa dose is divided into a first dose (20-35% of total) and continuous second doses, creating a segmented dosing regimen that prevents plasma concentration fluctuations and associated motor complications

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent implements continuous administration of levodopa through the second dose, ensuring stable plasma concentrations and continuous dopamine replacement, thereby eliminating the on-off fluctuations characteristic of traditional intermittent dosing

Inventive Principle:

Principle #20Continuity of useful action

2Reliability

If high levodopa doses are administered to maintain therapeutic effectiveness, then symptom control is improved, but total daily dose requirements increase leading to higher risk of side effects

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidtotal daily dose

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The first dose is administered at a high level (20-35% of total daily dose) to rapidly achieve therapeutic plasma concentrations, providing immediate symptom control while the continuous second doses maintain stable levels, allowing overall dose reduction

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach stabilizes dopamine levels, reducing the total daily dose by 30-40% while maintaining therapeutic effectiveness, minimizing motor fluctuations and dyskinesias, and allowing for personalized dosing adjustments based on patient sensitivity.

Implementation Method 1

dopamine is formed by decarboxylation of the precursor levodopa (L-dopa; L-3,4-dihydroxyphenylalanine) through the enzyme aromatic L-amino acid decarboxylase (also known as DOPA decarboxylase (DDC))

Methodology Applied

Scientific EffectDecarboxylation:

Implementation Method 2

a dopamine decarboxylase inhibitor (DDI)

Methodology Applied

Scientific EffectEnzyme inhibition:

Implementation Method 3

a catechol-O-methyltransferase (COMT) inhibitor

Methodology Applied

Scientific EffectEnzyme inhibition:

Data Source

PatentUS20250213518A1Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders

Publication Date: 2025.07.03 INTRANCE MEDICAL SYST INC

AI summary

A method of treating patients by using a pharmaceutical composition for intra-intestinal administration comprises (i) a dopamine replacement agents, (ii) a dopamine decarboxylase inhibitor (DDI), and (iii) a COMT inhibitor where the composition is continuously administered.